Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 600-609

  Glantz, M J ^a   Choy, H ^a   Kearns, C M ^a   Cole, B F ^a   Mills, P ^a   Zuhowski, E G ^a   Saris, S ^a   Rhodes, C H ^a   Stopa, E ^a   Egorin, M J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SKULL IRRADIATION;

EID: 9044234780     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.600     Document Type: Article

References (54)

1. Schiff PB, Funt J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 22:665-667, 1979
2. Parness J, Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479-487, 1981
3. Manfredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94:688-696, 1982
4. Cahan MA, Walter KA, Colvin OM, et al: Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33:441-444, 1994
5. Walter KA, Cahan MA, Gur A, et al: Interstitial Taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54:2207-2212, 1994
6. Helson L, Helson C, Malik S, et al: A saturation threshold for Taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drugs 4:487-490, 1993
7. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450-474, 1966
8. Tishler RB, Schiff PB, Geard CR, et al: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992
9. Tishler RB, Geard CR, Hall EJ, et al: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 51:3459-3497, 1992
10. Hei TK, Hall EJ: Taxol, radiation, and oncogenic transformation. Cancer Res 53:1368-1372, 1993
11. Choy H, Rodriguez FF, Koester S, et al: Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
12. Stern A, Sevin BU, Perras J, et al: Taxol sensitizes human ovarian cancer cells to radiation. Cancer Res 48:252-258, 1993
13. Milas L, Hunter NR, Mason KA, et al: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54:3506-3510, 1994
14. Kleihues P, Burger PC, Scheithauer BW: Histological Typing of Tumours of the Central Nervous System (ed 2). Berlin/Heidleberg, Germany, Springer-Verlag, 1993
15. Leibel SA, Scott CB, Pajak TF: The management of malignant gliomas with radiation therapy: Therapeutic results and research strategies. Semin Radiat Oncol 1:32-49, 1991
16. Leibel SA, Sheline GE: Radiotherapy for neoplasms of the brain. J Neurosurg 66:1-22, 1987
17. Loeffler JS, Alexander E: The role of radiotherapy in the management of astrocytomas, in Black PM, Schoene W, Lampson LA (eds): Astrocytomas: Diagnosis, Treatment and Biology. Boston, MA, Blackwell, 1993, pp 73-85
18. Curran WJ, Scott CB, Nelson JS, et al: A randomized trial of accelerated hyper-fractionated radiation therapy and bis-chlorethyl nitrosourea for malignant glioma. A preliminary report of radiation therapy oncology group 83-02. Cancer 70:2909-2917, 1992
19. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
20. D'Argenio DZ, Schumitsky A: ADAPT II User's Guide. Los Angeles, CA, Biomedical Simulations Resource, University of Southern California, 1990
21. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Prog Biomed 9:115-134, 1979
22. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23, 1995 (suppl 6)
23. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetics/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
24. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc 34:187-220, 1972
26. Shapiro WR: Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13:38-45, 1986
27. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911, 1980
28. Bashir R, Hochberg F, Oot R: Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23:27-30, 1988
29. Liang BC, Thornton AF Jr, Sandler HM, et al: Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 75:559-563, 1991
30. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993 (suppl 3)
31. Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al: Taxol in relapsed ovarian cancer: High versus low dose and short vs long infusion: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 12:256, 1993 (abstr)
32. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
33. Rowinsky EK, Donehower RC: The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20:16-25, 1993 (suppl 3)
34. Monsarrat B, Alvinerie P, Wright M, et al: Hepatic metabolism and biliary excretion of taxol in rats and humans. Monogr Natl Cancer Inst 15:39-46, 1993
35. Fetell MR, Grossman SA, Balmaceda C, et al: Clinical and pharmacologic study of pre-irradiation taxol administered as a 96 hour infusion in adults with newly diagnosed glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 13:179, 1994 (abstr)
36. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1994
37. Akerley W, Choy H, Rege V, et al: A phase I trial of weekly paclitaxel administered as a 3-hour infusion for metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:378, 1995 (abstr)
38. Ohtsu T, Sasaki Y, Tamura T, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599-606, 1995
39. Hurwitz CA, Relling MV, Weitman SD, et al: Phase I trial of paclitaxel in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol 11:2324-2329, 1993
40. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
41. Schiller JH, Storer B, Tutsch K, et al: Phase 1 trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
42. Lipton RB, Apfel SC, Dutcher JP, et al: Taxol produces a predominantly sensory neuropathy. Neurology 39:368-373, 1989
43. New P, Barohn R, Galex T, et al: Taxol neuropathy after long-term administration. Proc Am Assoc Cancer Res 32:1226, 1991
44. Rowinsky EK, Chaudhry V, Cornblath DR, et al: The neurotoxicity of Taxol. Monogr Natl Cancer Inst 15:107-115, 1993
45. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61:2192-2195, 1988
46. Cerosimo RJ: Cisplatin neurotoxicity. Cancer Treat Rev 16:195-211, 1989
47. Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66:1117-1123, 1990
48. Hovestadt A, van der Burg MEL, Verbiest HBC, et al: The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol 239:143-146, 1992
49. Rowinsky EK, Chaudhry V, Forastiere AA, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
50. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458-1467, 1994
51. Sheline GE, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6:1215-1228, 1980
52. Burger PC, Mahaley MS, Dudka L, et al: The morphologic effects of radiation administered therapeutically for intracranial gliomas: A postmortem study of 25 cases. Cancer 44:1256-1272, 1979
53. Pratt RA, DeCiro G, Week JC: Cerebral necrosis following irradiation and chemotherapy for metastatic choriocarcinoma. Surg Neurol 7:117-120, 1977
54. Curran WJ, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993